Class of molecules acting as modulators of SOCE, suitable for the treatment of rare diseases: TAM, Stormorken's syndrome and York's syndrome.
Proprietario: Università del Piemonte Orientale
Direct labelling which allows the early diagnosis of several pathologies, thanks to the conjugation of the chelators with sensible biomolecules.
Technology that uses ultrasounds to generate high-resolution images capable of providing biomedical, structural and functional information.
Nucleotide sequences for the selective expression of FVIII in endothelial and hematopoietic cells for the treatment of hemophilia.
Biological treatment with a immunological approach able to regulate all cellular mechanisms underlying bone erosion and regeneration.
The invention consists of a method for reprogramming induced pluripotent stem cells (iPSCs) for cellular and gene therapy of hemophilia A.
The patented technology allows to remove mineral oil, whose aromatic fraction is claimed to be cangerogenic.
Compounds potentially effective for the treatment of ultra-rare genetic pathologies related to calcium overload and loss of motorial capacity.
Formulation which inhibits metastatization by inhibiting the formation of new vessels and modulating the immune response against the tumor.
Safe gene and cellular therapy strategies, exploitable for the care either of coagulation disease or other genetic defects pathologies.
Use of SIRT1 enzyme’s inhibitors or antagonists for the prevention and/or treatment of diseases induced by human papillomavirus (HPV).